Citadel Advisors’s TG Therapeutics TGTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$10.2M Buy
307,100
+83,300
+37% +$2.48M ﹤0.01% 3228
2025
Q4
$6.67M Sell
223,800
-102,000
-31% -$3.33M ﹤0.01% 3847
2025
Q3
$11.8M Sell
325,800
-170,300
-34% -$5.61M ﹤0.01% 3023
2025
Q2
$17.9M Sell
496,100
-59,500
-11% -$2.22M ﹤0.01% 2282
2025
Q1
$21.9M Buy
555,600
+230,700
+71% +$7.76M ﹤0.01% 1941
2024
Q4
$9.78M Sell
324,900
-1,800
-0.6% -$51.7K ﹤0.01% 3015
2024
Q3
$7.64M Buy
326,700
+141,100
+76% +$3.08M ﹤0.01% 3307
2024
Q2
$3.3M Sell
185,600
-35,100
-16% -$560K ﹤0.01% 4413
2024
Q1
$3.36M Sell
220,700
-140,800
-39% -$2.24M ﹤0.01% 4598
2023
Q4
$6.17M Buy
361,500
+70,400
+24% +$818K ﹤0.01% 3508
2023
Q3
$2.43M Sell
291,100
-385,000
-57% -$5.37M ﹤0.01% 4866
2023
Q2
$16.8M Buy
676,100
+225,100
+50% +$5.81M ﹤0.01% 2063
2023
Q1
$6.78M Sell
451,000
-495,500
-52% -$7.53M ﹤0.01% 3324
2022
Q4
$11.2M Buy
946,500
+55,300
+6% +$401K ﹤0.01% 2669
2022
Q3
$5.28M Buy
891,200
+144,300
+19% +$946K ﹤0.01% 3770
2022
Q2
$3.17M Buy
746,900
+71,800
+11% +$448K ﹤0.01% 4657
2022
Q1
$6.42M Buy
675,100
+250,300
+59% +$2.9M ﹤0.01% 3703
2021
Q4
$8.07M Buy
424,800
+83,700
+25% +$2.17M ﹤0.01% 3434
2021
Q3
$11.4M Buy
341,100
+137,900
+68% +$4.27M ﹤0.01% 2847
2021
Q2
$7.88M Sell
203,200
-28,000
-12% -$1.1M ﹤0.01% 3526
2021
Q1
$11.1M Sell
231,200
-121,700
-34% -$5.85M ﹤0.01% 2818
2020
Q4
$18.4M Buy
352,900
+37,600
+12% +$1.27M ﹤0.01% 1899
2020
Q3
$8.44M Buy
315,300
+82,600
+35% +$1.9M ﹤0.01% 2490
2020
Q2
$4.53M Sell
232,700
-148,600
-39% -$2.39M ﹤0.01% 3220
2020
Q1
$3.75M Buy
381,300
+163,900
+75% +$2.07M ﹤0.01% 3123
2019
Q4
$2.41M Buy
217,400
+23,300
+12% +$177K ﹤0.01% 4108
2019
Q3
$1.09M Sell
194,100
-34,000
-15% -$237K ﹤0.01% 5449
2019
Q2
$1.97M Buy
228,100
+61,500
+37% +$465K ﹤0.01% 4531
2019
Q1
$1.34M Sell
166,600
-212,200
-56% -$1.15M ﹤0.01% 5088
2018
Q4
$1.55M Sell
378,800
-42,000
-10% -$209K ﹤0.01% 4569
2018
Q3
$2.36M Buy
420,800
+204,300
+94% +$2.33M ﹤0.01% 4131
2018
Q2
$2.85M Buy
216,500
+52,400
+32% +$721K ﹤0.01% 3563
2018
Q1
$2.33M Buy
164,100
+28,100
+21% +$359K ﹤0.01% 3498
2017
Q4
$1.11M Buy
136,000
+39,400
+41% +$344K ﹤0.01% 4509
2017
Q3
$1.15M Sell
96,600
-21,300
-18% -$243K ﹤0.01% 4131
2017
Q2
$1.19M Buy
117,900
+47,500
+67% +$532K ﹤0.01% 3849
2017
Q1
$820K Buy
+70,400
New +$505K ﹤0.01% 4288
2016
Q4
Sell
-13,400
Closed -$104K 7829
2016
Q3
$104K Buy
+13,400
New +$86.2K ﹤0.01% 6640
2016
Q2
Sell
-17,400
Closed -$148K 7398
2016
Q1
$148K Buy
17,400
+1,400
+9% +$12.3K ﹤0.01% 5838
2015
Q4
$191K Buy
16,000
+9,700
+154% +$123K ﹤0.01% 5860
2015
Q3
$64K Sell
6,300
-14,200
-69% -$212K ﹤0.01% 7397
2015
Q2
$340K Buy
20,500
+400
+2% +$6.33K ﹤0.01% 5576
2015
Q1
$311K Sell
20,100
-15,700
-44% -$238K ﹤0.01% 5599
2014
Q4
$567K Sell
35,800
-18,900
-35% -$246K ﹤0.01% 4548
2014
Q3
$584K Buy
54,700
+10,100
+23% +$93.7K ﹤0.01% 4410
2014
Q2
$419K Buy
44,600
+42,800
+2,378% +$274K ﹤0.01% 4629
2014
Q1
$12K Sell
1,800
-900
-33% -$5.33K ﹤0.01% 7466
2013
Q4
$11K Buy
+2,700
New +$10.9K ﹤0.01% 6688

Other funds holding TGTX

Citadel Advisors's TGTX Position: Q1 2026 in Review

Citadel Advisors increased its TG Therapeutics (TGTX) stake by 90% in Q1 2026, buying an estimated $27.2M and bringing the position to 1,922,889 shares worth $63.9M. The position accounts for 0.01% of the portfolio, ranked #1140.

Citadel Advisors first reported a position in TGTX in Q4 2013 and has held it in 48 quarters since. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

  • Citadel Advisors held 1,922,889 shares of TG Therapeutics worth $63.9M as of Q1 2026.
  • Citadel Advisors bought 911,852 TG Therapeutics shares in Q1 2026, an estimated $27.2M.
  • TG Therapeutics made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #1140 holding.
  • Citadel Advisors first reported a position in TG Therapeutics in Q4 2013 and has held it in 48 quarters since.
  • 363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.